New Vernon Capital Holdings II’s Catalyst Pharmaceutical CPRX Stock Holding History

New Vernon Capital Holdings II’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$335K	Hold	13,520	–	–	0.25%	25
2025 Q4	$316K	Hold	13,520	–	–	0.15%	36
2025 Q3	$266K	Hold	13,520	–	–	0.12%	45
2025 Q2	$293K	Sell	13,520 -314,340	-96%	-$7.42M	0.14%	39
2025 Q1	$13.5M	Buy	327,860 +322,038	+5,531%	+$7.25M	0.31%	28
2024 Q4	$122K	Buy	+5,822	New	+$125K	0.08%	61
2024 Q3	–	Sell	-7,864	Closed	-$122K	–	69
2024 Q2	$122K	Hold	7,864	–	–	0.07%	49
2024 Q1	$125K	Buy	+7,864	New	+$119K	0.06%	65

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

New Vernon Capital Holdings II's CPRX Position: Q1 2026 in Review

New Vernon Capital Holdings II held its Catalyst Pharmaceutical (CPRX) position steady in Q1 2026 at 13,520 shares worth $335K. The position accounts for 0.25% of the portfolio, ranked #25.

New Vernon Capital Holdings II first reported a position in CPRX in Q1 2024 and has held it in 8 quarters since. The position peaked at $13.5M in Q1 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

New Vernon Capital Holdings II held 13,520 shares of Catalyst Pharmaceutical worth $335K as of Q1 2026.
New Vernon Capital Holdings II left its Catalyst Pharmaceutical share count unchanged in Q1 2026.
Catalyst Pharmaceutical made up 0.25% of New Vernon Capital Holdings II's portfolio in Q1 2026, its #25 holding.
New Vernon Capital Holdings II first reported a position in Catalyst Pharmaceutical in Q1 2024 and has held it in 8 quarters since.
New Vernon Capital Holdings II's Catalyst Pharmaceutical position peaked at $13.5M in Q1 2025.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on New Vernon Capital Holdings II's 13F filing for Q1 2026, filed 15 May 2026.